Roche’s Vabysmo delivered sustained vision gains and improved retinal anatomy across three major retinal diseases in routine clinical practice, according to new real-world data from the VOYAGER study presented at the EURETINA 2026 Annual Meeting in Vienna.

 

The study evaluated the effectiveness, durability and safety of Vabysmo (faricimab) in neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO).

 

Across the study cohorts, the findings were consistent with results from Vabysmo’s Phase III trials, showing vision gains and substantial anatomical improvements in previously untreated eyes, while previously treated eyes maintained or improved vision alongside improved retinal anatomy.

 

In the nAMD and DME cohorts, previously untreated patients experienced improvements in vision and central subfield thickness (CST) after 12 months of Vabysmo treatment. Previously treated patients maintained stable vision while showing improved CST.

 

The RVO cohorts also showed improvements. In central/hemi-RVO, both previously untreated and treated eyes saw improvements in vision and CST after six months of treatment.3 In branch RVO, previously untreated eyes improved in both vision and CST, while previously treated eyes maintained stable vision and showed improved CST.

 

“These real-world results underscore how the efficacy and safety observed in our pivotal Vabysmo studies translate directly into routine clinical practice globally,” said Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development. 

 

“The sustained visual improvements and meaningful anatomical drying seen in the VOYAGER study reinforce the role of Vabysmo in helping to address important unmet needs for patients with retinal conditions.”

 

“In daily clinical practice, we manage diverse patient populations with complex treatment histories who don’t always mirror the strict entry criteria of controlled Phase III trials.” said Professor Robyn Guymer, Chair of the VOYAGER Steering Committee and Deputy Director of the Centre for Eye Research Australia. 

 

“The latest VOYAGER data give physicians from across the world the confidence that Vabysmo delivers sustained visual gains, meaningful anatomical drying, and an established safety profile in everyday practice – whether a patient is starting treatment for the first time or transitioning from another therapy.”

 

The latest VOYAGER findings reinforce the consistency of Vabysmo’s real-world performance across diverse clinical settings. Across all cohorts, subretinal fluid (SRF) and intraretinal fluid (IRF) were consistently reduced in both previously untreated and previously treated eyes.

 

The data also point to the potential for longer treatment intervals. In the nAMD and DME cohorts, patients received fewer Vabysmo injections during months 7-12 than during the first six months, suggesting that treatment intervals were extended over time.